Pharmaceuticals
J&J to spin off orthopedics business, raises full-year forecast
Johnson & Johnson said on Tuesday it plans to separate its orthopedics business into a standalone company named DePuy Synthes within the next 18 to 24 months, marking its second major spinoff in two years. The health-care conglomerate also raised its 2025 sales forecast after reporting quarterly earnings that topped Wall Street expectations. The company […]
Read More
Forget Trump’s tariffs — here’s what is separating pharma’s winners and losers
The pharmaceutical industry has been making headlines recently, after the administration of U.S. President Donald Trump slapped 100% tariffs on branded and patented drugs But investors say drugmakers’ carve-out agreements on pricing is what will rattle the sector — and create a range of winners and losers as a result. Global pharmaceutical companies who have broken […]
Read More
Trump’s pharmaceutical tariff threat loses bite after Pfizer deal reassures drugmakers
U.S. President Donald Trump shakes hands with Pfizer CEO Albert Bourla (L) as he announces a deal with Pfizer to lower Medicaid drug prices in the Oval Office of the White House on September 30, 2025 in Washington, DC. Win Mcnamee | Getty Images President Donald Trump’s long-awaited threat to impose pharmaceutical tariffs may not […]
Read More
CDC takes down more than a dozen webpages on sexual and gender identity, health equity
A sign for the CDC sits outside of their facility at the Centers for Disease Control and Prevention Roybal campus in Atlanta, Georgia, U.S., May 30, 2025. Megan Varner | Reuters More than a dozen pages on the Centers for Disease Control and Prevention website related to sexual and gender identity, health equity, and other […]
Read More
U.S. pharma tariffs spare India’s generic drugmakers — but leave investors jittery
MUMBAI, INDIA – MARCH 3: A technician works at a Cipla laboratory March 3, 2002 in Vikhrohi, Mumbai, India. Jean-marc Giboux | 3rd Party – Misc | Getty Images Stocks of leading Indian drugmakers fell on Friday, even though the 100% U.S. tariffs on branded and patented drug imports are unlikely to affect these companies. […]
Read More
Why Trump’s 100% drug tariffs could hit Asia and Europe very differently
Global pharmaceutical stocks sold off on Friday, as markets reacted to news of 100% tariffs on branded and patented drugs imported into the United States, but significant moves lower haven’t been across the board. While Asia Pacific-listed shares in the sector saw notable falls — with some stocks tumbling more than 5% — the reaction […]
Read More
U.S. to impose 100% tariff on branded, patented drugs unless firms build plants locally, Trump says
Shelf of pharmaceutical products. D3sign | Moment | Getty Images President Donald Trump announced Thursday that the U.S. will impose a 100% tariff on “any branded or patented Pharmaceutical Product” entering the country from Oct. 1. The measure will not apply to companies building drug manufacturing plants in the U.S., Trump added. He said that […]
Read More
Roche targets becoming top 3 obesity player as experimental drug enters late-stage trial
The Roche Holding AG headquarters on April 11, 2025, in Basel, Switzerland. Sedat Suna | Getty Images News | Getty Images Swiss pharmaceutical firm Roche is targeting becoming a top three obesity player globally, posing a potential rival to heavyweights Novo Nordisk and Eli Lilly as it advances one of its experimental weight-loss drugs to […]
Read More
The Trump administration is changing Covid, childhood vaccine recommendations – here’s what it means for you
A proposed vote by Massachusetts Institute of Technology professor Retsef Levi is displayed during an Advisory Committee on Immunization Practices (ACIP) meeting at the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia, U.S., Sept. 19, 2025. Alyssa Pointer | Reuters New recommendations last week from an influential vaccine panel handpicked by Health and […]
Read More
Eli Lilly to build $6.5 billion Texas manufacturing facility for obesity pill, other drugs
A rendering of Eli Lilly’s manufacturing facility in Houston, Texas. Courtesy: Eli Lilly Eli Lilly on Tuesday said it will spend $6.5 billion to build a manufacturing facility in Houston, Texas, to boost production of the company’s pipeline of so-called small molecule drugs, including its closely watched experimental obesity pill. It is the second in […]
Read More